FIM
BMRN icon

Foresters Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Foresters Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,623
Closed -$323K – 414
2017
Q4 		$323K Buy
3,623
+690
+24% +$60K 0.01% 435
2017
Q3 		$273K Buy
2,933
+440
+18% +$38.9K ﹤0.01% 437
2017
Q2 		$226K Buy
2,493
+1,667
+202% +$152K ﹤0.01% 443
2017
Q1 		$73K Buy
+826
New +$73.5K ﹤0.01% 391

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Foresters Investment Management's BMRN Position: Q1 2018 in Review

Foresters Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2018, closing a stake of 3,623 shares — an estimated $323K sold.

Foresters Investment Management first reported a position in BMRN in Q1 2017 and held it in 4 quarters. The position peaked at $323K in Q4 2017. 429 funds tracked by Wall St. Rank hold BMRN as of Q1 2018.

  • Foresters Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Foresters Investment Management sold 3,623 BioMarin Pharmaceuticals shares in Q1 2018, an estimated $323K.
  • Foresters Investment Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Foresters Investment Management's BioMarin Pharmaceuticals position peaked at $323K in Q4 2017.
  • 429 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2018.

Based on Foresters Investment Management's 13F filing for Q1 2018, filed 11 May 2018.